Edit |   |
---|---|
Antigenic Specificity | GSK3B pS9, Human/Mouse/Rat |
Clone | REA436 |
Host Species | Recombinant Human |
Reactive Species | human, mouse, rat, other |
Isotype | IgG1 |
Format | phycoerythrin (PE) conjugate |
Size | 100 tests in 1 mL |
Concentration | 1:11 |
Applications | Intracellular flow cytometry |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | GSK3B pS9 Antibody, anti-human/mouse/rat, PE, REAfinity™. Clone REA436 recognizes the human, mouse, and rat glycogen synthase kinase-3 β (GSK3B) phosphorylated at serine 9 (pS9). The GSK-3 family of protein-serine kinases was initially characterized as a regulator of glycogen metabolism. The protein kinase phosphorylates residues on glycogen synthase, the rate-limiting enzyme of glycogen synthesis, that are specifically dephosphorylated in response to insulin. In mammals, two genes encode closely related proteins termed GSK3A and GSK3B. The kinase is highly conserved and has roles in a number of signal transduction pathways regulating cell growth, differentiation, and development. GSK3B activity is regulated negatively by the phosphorylation of serine 9. | Additional information: Clone REA436 displays negligible binding to Fc receptors. |
Immunogen | n/a |
Other Names | GSK3B, GSK-3, GSK-3beta |
Gene, Accession # | Gene ID: 56637, 84027 |
Catalog # | 130-106-900 |
Price | $335 |
Order / More Info | GSK3B pS9, Human/Mouse/Rat Antibody from MILTENYI BIOTEC B.V. & Co. KG |
Product Specific References | Stambolic, V. et al. (1994) Mitogen inactivation of glycogen synthase kinase-3 beta in intact cells via serine 9 phosphorylation. Biochem. J. 303 (Pt 3): 701-704. | Cai, G. et al. (2007) Phosphorylation of glycogen synthase kinase-3 beta at serine 9 confers cisplatin resistance in ovarian cancer cells. Int. J. Oncol. 31 (3): 657-662. | Giovannini, C. et al. (2013) Notch3 inhibition enhances sorafenib cytotoxic efficacy by promoting GSK3b phosphorylation and p21 down-regulation in hepatocellular carcinoma. Oncotarget. 4 (10): 1618-1631. |